SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axisAnthony Williams(University of Chicago), Russell Z. Szmulewitz(University of Chicago)Cancer LettersMay 9, 202310.1016/j.canlet.2023.216209Cited by 16SaveCiteExport RISWatch citationsRelated PapersProspective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study|Journal of Clinical Oncology|2019|364Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3|Journal for ImmunoTherapy of Cancer|2015|101